z-160
Small moleculeexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2012 (NCT01655849)
Timeline
2010s
- Jan 1, 2012
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
CACNA1B blocker
Indication: Lumbosacral Radiculopathy, Postherpetic Neuralgia
Chemistry & pharmacology
Loading structure…
SMILES
O=C(CC(c1ccccc1)c1ccccc1)N1CCN(C(c2ccccc2)c2ccccc2)CC1- Mol. weight
- 460.62 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL604710 ↗
Also known as
- 1-(4-benzhydrylpiperazin-1-yl)-3,3-diphenylpropan-1-one
- mk-6721
- mk-6721
- nmed-160
- nmed-160
- np118809
- np 118809
- np-118809
- np-118809
- np-118809
- z160
- z160
- z160
- z-160
- z-160
- z-160
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01757873 | Phase 2 | Dec 1, 2012 | Zalicus |
| NCT01655849 | Phase 2 | Aug 1, 2012 | Zalicus |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Zalicus | For profit | 2 | 2 | 1 | 2012 |
1 organizations
Page 1 / 1